HomeMarket NewsSmall CapsWhy Is Heart Failure-Focused CVRx Stock Trading Higher Today?

Why Is Heart Failure-Focused CVRx Stock Trading Higher Today?

Actionable Trade Ideas

always free

CVRx IncΒ CVRX announced that the Centers for Medicare and Medicaid Services (CMS) has reassigned the Barostim implant procedure for procedures performed in the outpatient setting as part of the 2024 Medicare Hospital Outpatient Prospective Payment SystemΒ (OPPS) final rule.

Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.

In the 2024 OPPS final rule, Barostim was reassigned to New Technology APC 1580, which carries an average payment of $45,000. The new payment takes effect January 1, 2024.Β 

In 2023, Barostim was assigned to APC 5465, which carries an average payment amount of $29,000, with a Transitional Pass-Through Payment set to expire on December 31, 2023.

β€œWe sincerely appreciate the consideration taken by CMS of the resource requirements associated with the Barostim implant procedure. We believe that reassignment to APC 1580 will facilitate increased access to the therapy for Medicare patients with heart failure by offering facilities sufficient reimbursement for the procedure,” said Nadim Yared, President and CEO of CVRx.Β 

Price Action:Β CVRX shares are up 25.50% at $17.09 on the last check Friday.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.